Profile data is unavailable for this security.
About the company
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)2.60bn
- Net income in CNY740.69m
- Incorporated1996
- Employees1.96k
- LocationXiamen Amoytop Biotech Co LtdNo.330 Wengjiao RoadHaicang Xinyang Industry ZoneXIAMEN 361028ChinaCHN
- Phone+86 5 926889118
- Fax+86 5 926889130
- Websitehttp://www.amoytop.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.35bn | 1.14bn | 27.35bn | 8.22k | 24.00 | 3.11 | -- | 2.93 | 0.7772 | 0.7772 | 6.34 | 5.99 | 0.4922 | 1.02 | 3.51 | 1,137,186.00 | 6.01 | 5.67 | 8.37 | 8.07 | 61.97 | 60.52 | 12.21 | 11.61 | 0.7919 | 6.25 | 0.4541 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Kangmei Pharmaceutical Co Ltd | 5.21bn | 255.55m | 28.01bn | 4.41k | 109.07 | 3.98 | -- | 5.37 | 0.0185 | 0.0185 | 0.3766 | 0.5079 | 0.3626 | 1.45 | 2.55 | 1,182,457.00 | 1.80 | -17.60 | 2.77 | -32.24 | 20.63 | -72.78 | 4.95 | -101.19 | 0.8398 | -- | 0.0346 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 28.33bn | 5.23k | 10.15 | 2.01 | -- | 3.18 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Gan & Lee Pharmaceuticals | 2.95bn | 580.86m | 29.00bn | 4.48k | 49.37 | 2.59 | -- | 9.84 | 0.9773 | 0.9773 | 4.97 | 18.65 | 0.2558 | 0.8458 | 8.94 | 657,602.00 | 5.04 | 8.30 | 5.40 | 8.83 | 72.92 | 85.39 | 19.71 | 26.44 | 6.77 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Bluestar Adisseo Co | 14.95bn | 1.09bn | 30.98bn | 2.73k | 28.42 | 1.96 | -- | 2.07 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Xiamen Amoytop Biotech Co Ltd | 2.60bn | 740.69m | 31.68bn | 1.96k | 42.77 | 13.99 | -- | 12.21 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Humanwell Healthcare Group Co Ltd | 25.56bn | 1.96bn | 34.55bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
Data as of Sep 13 2024. Currency figures normalised to Xiamen Amoytop Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
11.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yunnan International Trust Co., Ltd.as of 30 Jun 2024 | 12.01m | 2.95% |
| Tibet Trust Corp. Ltd.as of 30 Jun 2024 | 8.24m | 2.03% |
| Allianz Insurance Asset Management Co., Ltd.as of 30 Jun 2024 | 6.18m | 1.52% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 5.94m | 1.46% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 3.89m | 0.96% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.87m | 0.46% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.83m | 0.45% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 1.75m | 0.43% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.71m | 0.42% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 1.47m | 0.36% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
